Platelets News and Research

RSS

Anti-platelet drug class fails to extend survival in moderately ill COVID-19 patients

A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or lessen disease severity in patients with COVID-19 who were hospitalized but had a relatively moderate case, a new study finds.

15 Nov 2021

Platelet inhibitors may be linked with reduction in digital ulcers in people with systemic sclerosis

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that use of platelet inhibitors could be associated with a reduction in the occurrence of digital ulcers, painful sores on the extremities that can progress to gangrene, in people with systemic sclerosis.

1 Nov 2021

Personalized clotting profiles could benefit people at risk from strokes and heart attacks

People at risk from strokes and heart attacks could benefit from personalized clotting profiles to help clinicians prescribe more precise treatments, thanks to new research.

20 Oct 2021

A possible protective genetic polymorphism in COVID-19

A new study discusses the role of a mucin gene enhancer on the clinical phenotype of the COVID-19.

5 Oct 2021

Scientists identify emerging infectious disease caused by a new nairovirus in Japan

A previously unknown virus that can infect humans and cause disease has been identified by scientists in Japan.

4 Oct 2021

Scientists offers new hope for future treatment of sepsis

Sepsis, the body's life-threatening response to infection affecting about 1.7 million adults in the United States each year, can lead to multisystem organ failure with a high mortality rate.

29 Sep 2021

Classic antidepressants show potential to enhance modern cancer treatments

Classic antidepressants could help improve modern cancer treatments. They slowed the growth of pancreatic and colon cancers in mice, and when combined with immunotherapy, they even stopped the cancer growth long-term.

28 Sep 2021

Review of COVID-19 clinical and viral characteristics, pathogenesis, and genetics

A new review article investigates the clinical and viral characteristics, pathogenesis, as well as human genetic basis associated with COVID-19.

27 Sep 2021

Changes in fibrin clot structure contributes to thrombosis risk in severe COVID-19

Researchers from Europe recently demonstrated altered levels of factor XII (FXII) and its activation products in 2 independent cohorts of critically ill patients with COVID-19 compared to patients suffering from severe acute respiratory distress syndrome caused by the influenza virus (acute respiratory distress syndrome (ARDS)-influenza).

21 Sep 2021

First dose of COVID-19 mRNA vaccine (BNT162b2) reduced platelet polyP levels in young females

In a recent study, scientists have tested the hypothesis that indicates the role of polyP in the COVID-19 mRNA vaccine-induced immune responses.

20 Sep 2021

Novel combination therapy approach to keep leukemia at bay

In chronic leukemias, blocking the overactive kinase JAK2 by a targeted therapy approach is only mitigating the patients' symptoms, but cannot truly change the course of the disease.

16 Sep 2021

Allergic reactions provide protection against yeast-triggered asthma, research shows

We think of asthma and other allergic diseases as unnecessary aberrant immune responses that do more harm than good. However, new evidence by an international team led by researchers at Baylor College of Medicine shows that some allergic reactions provide necessary protection against highly invasive and potentially lethal infectious agents, such as yeast.

9 Sep 2021

Research reveals a new role for platelets in COVID-19 blood vessel damage

Abnormal crosstalk between blood platelets and cells lining blood vessels is one cause of deadly organ damage in patients with severe COVID-19, a new study finds.

8 Sep 2021

Understanding platelets in COVID-19 may help identify diagnostic markers and treatments

Researchers in the United States and Japan have provided novel insights into the pathologic mechanisms underlying coronavirus disease 2019 (COVID-19) that may aid the identification of potential diagnostic biomarkers and treatment targets.

8 Sep 2021

The impact of mild SARS-CoV-2 infection on maternal-fetal immunity

Recently, a new study published on the pre-print server bioRxiv* examined the effect that maternal asymptomatic COVID-19 had on decidual and peripheral immune cells during the later stage of pregnancy.

30 Aug 2021

Adding berzosertib to standard treatment for metastatic urothelial cancer does not extend patient survival

A Phase 2 trial led by City of Hope, a world-renowned research and treatment center for cancer and diabetes, suggests that adding the novel ataxia telangiectasia and Rad3-related (ATR) inhibitor drug berzosertib to standard-of-care chemotherapy for patients with metastatic urothelial cancer does not extend progression-free survival.

27 Aug 2021

The influence of COVID-19 on platelet activation and aggregation

In a paper recently uploaded to the bioRxiv* preprint server, humanized ACE2 mice are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and platelets are subsequently isolated from the blood for quantitative proteomic analysis.

26 Aug 2021

Persistence of Anti-PF4 levels in VITT patients four months after AstraZeneca COVID-19 vaccine

A study published on medRxiv* preprint server reported the over-time changes in the ability of the serum to activate platelets in vitro.

25 Aug 2021

SARS-CoV-2 Spike may trigger production of antibodies that cross-react with human thrombopoietin to induce thrombocytopenia

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected individuals often suffer from thrombocytopenia, a condition associated with low platelet counts. The cytokine thrombopoietin regulates platelet count. Previous studies have reported that thrombocytopenia can increase the coronavirus disease 2019 (COVID-19) mortality rate by about five times.

16 Aug 2021

Innovative therapeutic platform for blood-to-brain delivery of antisense oligonucleotide therapy

Antisense oligonucleotide (ASO) therapy has the potential to ameliorate many neurodegenerative diseases at the genetic level to suppress the production of harmful proteins or non-coding RNAs.

12 Aug 2021